Board of Directors

Dean Calhoun

See Dean's biography.

Michael E. Hart

From 2001 to 2006, Mike served as President, Chief Executive Officer and Chief Financial Officer for Allos Therapeutics, Inc. and was elected to their Board of Directors in January 2002. From 1999 to December 2001, Mr. Hart served as Allos' Chief Financial Officer and Senior Vice President, Operations. From 1995 to 1999, Mr. Hart was Vice President and Chief Financial Officer of NeXstar Pharmaceuticals, Inc., where he also served as Chairman of the Management Committee from 1998 to 1999. From 1990 to 1995, Mr. Hart was Executive Vice President and Chief Financial Officer of Vestar, Inc. and served as Chairman, Office of the President from 1994 to 1995. From 1982 to 1990, Mr. Hart was Treasurer and Director of Finance for Avantek, Inc. and prior to that held various financial positions with high technology companies.

Mr. Hart received his M.B.A from California State University, Fresno, and his undergraduate degrees in business economics and geography from the University of California, Santa Barbara.

Christopher Tompkins

Christopher is Vice President of Operations and Chief Compliance Officer for Atrius Bioscience, LLC. Prior to Atrius he was General Manager for Proligo's North and South American oligonucleotide business. As General Manager, he oversaw a three fold growth of the business and led the transition of the oligonucleotide product line from DNA to specialty RNA. Also as General Manager, Christopher negotiated and secured supply contracts with several major pharmaceutical companies and also led the global team responsible for developing a secure, integrated and automatic supply chain linking Proligo to the end users at major pharmaceutical research centers throughout North America.

Christopher Tompkins graduated with a Ph.D. in Chemical Engineering from North Carolina State University, and has worked for Hoffmann-La Roche, where he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda (Capecitabine), and NeXstar Pharmaceuticals where he designed the reactor technology used to produce the macular degeneration treatment, Macugen, and founded the process engineering group responsible for the engineering development and scale-up of oligonucleotide based pharmaceuticals.